Kate E. Gehl

Senior Counsel

Kate E. Gehl

Senior Counsel

Kate Gehl is an antitrust and competition lawyer who provides strategic counsel to clients in the areas of antitrust litigation and investigations, including civil and criminal enforcement. With a reputation for practical advice, Kate routinely counsels clients across numerous industries on business matters related to antitrust and competition.

Kate primarily works with companies in the technology, manufacturing, pharmaceuticals, life sciences, and health care sectors. Kate is a seasoned litigator with over a decade of experience handling high-stakes cases. She listens to her clients’ needs and obtains a full understanding of their business, which provides results. Kate’s time as a former federal judicial clerk also makes her uniquely qualified to provide insightful strategic advice on litigation strategy, with an inside perspective.

In addition to her antitrust investigation and litigation practice, Kate regularly provides antitrust guidance related to intellectual property licensing, including licensing practices related to standard essential patents and patent pools, participation in trade associations, industry organizations and standard setting organizations, product distribution and supply chain logistics, e-commerce, joint ventures and commercial agreements, collaborations with competitors, and general antitrust compliance. Kate has particular experience litigating antitrust issues that arise in the context of patent infringement litigation or other disputes involving intellectual property.

Parallel to her antitrust litigation practice, Kate maintains a practice representing businesses in complex commercial litigation. She has significant experience in complex electronic discovery and has worked with experts to develop reports and testimony, and she has written briefs and motions at all stages of litigation in federal and state courts across the country.

 

Awards and Recognition

  • Wisconsin Super Lawyers – Rising Stars® list (2019)

Affiliations

  • Current vice chair of the ABA Antitrust Law Section Intellectual Property Committee; actively involved in local bar activities in the State of Wisconsin, the Eastern District of Milwaukee and the Seventh Circuit.

Community Involvement

  • Pro bono representation through the Milwaukee Justice Center and with the Eastern District of Wisconsin Bar Association’s Federal Legal Assistance Program.

Presentations and Publications

Kate regularly publishes and speaks on antitrust and compliance issues. The following represents a sampling of her work:

11 December 2023 - 15 December 2023 Events

Virtual CLE Week

Please join Foley for Milwaukee's Annual CLE Weeks. This year’s programs will be presented over six days and will cover a range of key business, industry, and ethics topics. As a unique offering this year, CLE Weeks will provide both in-person and virtual session topics
04 December 2023 - 08 December 2023 Events

Milwaukee CLE Week

Please join Foley for Milwaukee's Annual CLE Weeks. This year’s programs will be presented over six days and will cover a range of key business, industry, and ethics topics. As a unique offering this year, CLE Weeks will provide both in-person and virtual session topics
27 November 2023 Innovative Technology Insights

FTC Weighs in on Threats to Competition from Artificial Intelligence in Comment to U.S. Copyright Office

The FTC is focused on the impact of AI on competition, suggesting that certain actions may violate Section 5 of the Federal Trade Commission Act.
17 November 2023 PharmaPatents

Revisiting FDA’s Original Guidance on Orange Book Listability in Light of Heightened FTC Scrutiny

The listing of many types of patents in the FDA’s Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) is fairly straightforward
12 October 2023 Events

Top Trends to Watch in Pharmaceutical Litigation

As the Health Care & Life Sciences sector continues to evolve, organizations across the country should be mindful of recent trends in pharmaceutical litigation.
18 September 2023 Blogs

Federal Trade Commission Warns Against Improper Orange Book Listings

As announced in a September 14, 2023, press release, the FTC has issued a policy statement “warning pharmaceutical companies that make and sell brand-name drugs that they could face legal action if they improperly list patents in the FDA’s [Orange Book].”